Covidien begins enrollment in a pair of clinical studies evaluating its Stellarex drug-coated angioplasty balloon in the U.S. and abroad.
Covidien (NYSE:COV) kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon.
The Massachusetts-based company started enrolling patients with peripheral arterial disease in the Pivotal and PK arms of its larger ILLUMENATE clinical trials examining the safety and effectiveness of Covidien’s Stellarex devices.